(Q36471229)

14 August 2017

1 reference

title

Bone markers and current laboratory assays (English)

1 reference

14 August 2017

2

Richard Eastell

1 reference

14 August 2017

1

Rosemary A Hannon

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

Cancer Treatment Reviews

1 reference

14 August 2017

32 Suppl 1

1 reference

14 August 2017

7-14

1 reference

Metastasis to bone: causes, consequences and therapeutic opportunities

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Crosstalk between cancer cells and bone microenvironment in bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Endothelin-1 and osteoblastic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Investigation of bone disease using isomerized and racemized fragments of type I collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Markers of bone turnover in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Minireview: the OPG/RANKL/RANK system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Preanalytical variability of biochemical markers of bone turnover.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Effect of feeding on bone turnover markers and its impact on biological variability of measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Clinical use of markers of bone turnover in metastatic bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Bone remodeling markers in the detection of bone metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

The role of markers of bone remodeling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Comparison of urinary markers for bone resorption in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Biochemical markers of bone turnover in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2806%2980003-4

7 January 2021

10.1016/S0305-7372(06)80003-4

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16680832